rethinkTHC Search
Menu
Study breakdown

Key questions about cannabis and road safety remain unanswered as legalization expands

ReviewModerate evidence
The takeaway

Despite growing evidence that cannabis increases crash risk, fundamental questions about dose-response relationships, tolerance effects, edible impairment timelines, and medical vs recreational user differences remain unresolved.

Policymakers, law enforcement, medical cannabis patients who drive, road safety researchers

Dose-response relationship between cannabis and driving impairment remains unclear

What the researchers found

Cannabis contributes to crash risk, but key questions remain unanswered: the dose-response relationship is unclear, tolerance effects on driving are uncertain, different routes of administration (edibles, vaping) have different impairment timelines, and whether medical users are impaired differently from recreational users is unknown.

Why it matters

Canada and other jurisdictions legalized cannabis with road safety as a central concern, but the evidence needed to inform effective impaired driving policies has significant gaps that urgently need filling.

The numbers in context

Canada legalized non-medical cannabis October 2018; Uruguay in December 2013; evidence covers crash risk, impairment duration, and detection methods

How the study worked

Narrative review identifying and discussing key questions about cannabis and road safety, drawing on epidemiological, behavioral, and pharmacological evidence.

What this study cannot tell us

Many referenced studies use cannabis potencies lower than currently available products. Most driving research involves simulated rather than real-world driving. Sex differences in cannabis pharmacology and driving effects are understudied.

How to read the evidence

Narrative review synthesizing evidence across multiple research domains related to cannabis and road safety

When this study was published

Published in 2021, shortly after Canada became the second country to legalize non-medical cannabis.

The bigger picture

The cannabis-driving research gap is concerning because policies are being implemented based on incomplete evidence. Unlike alcohol, where the dose-response relationship with impairment is well-established, cannabis lacks equivalent scientific foundations for regulation.

Questions still open

  • Is there a reliable dose-response curve for cannabis and driving impairment? Should medical cannabis users face the same driving restrictions as recreational users? How do edibles affect driving compared to inhaled cannabis?

Common questions

Does cannabis impair driving?
Evidence shows cannabis contributes to crash risk, but key details like the dose-response relationship, how long impairment lasts, and how tolerance affects driving ability remain unclear.
Are medical cannabis users impaired when driving?
Whether medical users, who may develop tolerance, are impaired differently from recreational users is an important unanswered question. No definitive research has established this distinction.

Read the original research

Cannabis, Impaired Driving, and Road Safety: An Overview of Key Questions and Issues.

Frontiers in psychiatry, 12, 641549

Citation

Brands, Bruna; Di Ciano, Patricia; Mann, Robert E. (2021). Cannabis, Impaired Driving, and Road Safety: An Overview of Key Questions and Issues.. Frontiers in psychiatry, 12, 641549. https://doi.org/10.3389/fpsyt.2021.641549